Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10267-10273

  Xu, Donghua ^a   Wang, Xiaochen ^a   Yan, Shushan ^a   Yin, Yin ^a   Hou, Jiajie ^a   Wang, Xuehao ^a   Sun, Beicheng ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; NF B; Protein tyrosine phosphatase receptor typeO; Toll like receptor 4

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PTPRO PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSFECTION;

EID: 84922393603     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2302-5     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7:242-54.
3. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1:2-14.
4. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology. 2006;44:287-98.
5. Matijevic T, Pavelic J. Toll-like receptors: cost or benefit for cancer? Curr Pharm Des. 2010;16:1081-90.
6. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology. 2010;52:1322-33.
7. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27: 218-24.
8. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317: 121-4.
9. Wang Z, Yan J, Lin H, Hua F, Wang X, Liu H, et al. Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatology. 2013;57:1869-81.
10. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57:678-88.
11. Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A. 2004;101:13844-9.
12. Huang YT, Li FF, Ke C, Li Z, Li ZT, Zou XF, et al. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J TranslMed. 2013;11:245.
13. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 2008;27:234-43.
14. Wei XQ, Guo YW, Liu JJ, Wen ZF, Yang SJ, Yao JL. The significance of toll-like receptor 4 (TLR4) expression in patients with chronic hepatitis B. Clin Invest Med. 2008;31:E123-30.
15. Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, et al. Circulating tolllike receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS. 2010;118:261-70.
16. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106:1548-53.
17. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 2005;28:886-92.
18. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst. 2005;97:1778-81.
19. Mai CW, Kang YB, Pichika MR. Should a toll-like receptor 4 (TLR- 4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Oncol Targets Ther. 2013;6:1573-87.
20. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504-16.
21. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117:699-711.
22. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:3174-81.
23. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428-33.
24. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117:2713-22.
25. Hou J, Xia Y, Jiang R, Chen D, Xu J, Deng L, et al. PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-kappaB. J Hepatol. 2014;60:306-12.
26. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature. 2004;431:461-6.
27. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206:193-9.
28. Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell StemCell. 2013;12:761-73.
29. Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, Isbir T, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381.
30. Li P, Gu J, Yang X, Cai H, Tao J, Lu Q, et al. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One. 2013;8: e71604.
31. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246: 379-400.